Approach to the Patient: Pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta.

Winnie LiuBrendan LeeSandesh C S NagamaniLindsey NicolFrank RauchEric T RushV Reid SuttonEric S Orwoll

Published in: The Journal of clinical endocrinology and metabolism (2023)

Fracture rates are elevated in adults with OI. Although clinical trial data are limited, bisphosphonates and teriparatide may be useful in improving BMD. Further research is needed to develop medications for adults with OI that will lead to definite fracture rate reduction.

Keyphrases

clinical trial
hip fracture
case report
electronic health record
randomized controlled trial
open label
study protocol
phase ii
postmenopausal women
phase iii